TABLE 1.

Modification of the vaccine/placebo hazard ratio of HIV-1 acquisition by FcγR SNPs and haplotypes in HVTN 505

Gene	SNP	Genotype or haplotype	No. of cases (vaccine:placebo)	HRa	95% CI	P valueb	Interaction P valuec	Interaction q valuec
FCGR3B	FCGR3B-5'utr44-T/A (rs34322334)	TT	10:16	0.66	0.29, 1.5	0.317	0.033	0.178
		TA/AAd	14:5	2.84	0.98, 8.18	0.054
	FCGR3B-5'utr99-C/G (rs61803026)	CC	9:14	0.68	0.29, 1.6	0.375	0.032	0.178
		CG/GGd	18:7	2.6	1.06, 6.37	0.036
	FCGR3B-5'utr222-G/A (rs34085961)	GG	10:16	0.65	0.29, 1.49	0.308	0.023	0.178
		GA/AAd	15:5	3.07	1.07, 8.75	0.036
FCGR2C	FCGR2C-exon06-441-C/T (rs138747765)	CC	17:20	0.86	0.44, 1.7	0.667	0.034	0.178
		CT/TTd	9:1	9.79	1.17, 81.78	0.035
	FCGR2C-intron06-590-G/A (rs78603008)	GG	17:20	0.86	0.44, 1.7	0.667	0.034	0.182
		GA/AAd	9:1	9.79	1.17, 81.78	0.035
	FCGR2C-intron15-403-C/T (rs373013207)	CC	15:18	0.88	0.43, 1.78	0.719	0.045	0.182
		CT/TTd	12:3	3.92	1.08, 14.16	0.037
	FCGR2C-intron15-433-G/A (rs201984478)	GG	13:17	0.82	0.39, 1.73	0.601	0.042	0.182
		GA/AAd	14:4	3.33	1.08, 10.29	0.036
		CT/TTd	11:4	2.14	0.6, 7.55	0.239
FCGR3B		FCGR3B-AGA
		−	11:16	0.73	0.33, 1.62	0.439	0.047
		+	14:5	2.78	0.97, 7.94	0.057
FCGR2C		FCGR2C-TATA
		−	17:20	0.86	0.44, 1.7	0.667	0.034
		+	9:1	9.79	1.17, 81.78	0.035

^aVaccine/placebo hazard ratio of HIV-1 acquisition in HVTN 505 for individuals with the given genotype at the given SNP.

^bP value of testing for HR = 1 for individuals with the given genotype at the given SNP.

^cInteraction P value of testing for a difference in HR between the two indicated genotype groups. Boldface indicates P ≤ 0.05 and q ≤ 0.2.

^dThe genotypes containing at least one minor allele.